Shanghai – November 05, 2026 -- Dizal (SSE: 688192) will present three oral and five poster presentations from its hematological disease portfolio at the 68th American Society of Hematology (ASH) Annual Meeting, including the first clinical data for its EZH1/2 inhibitor GW5282 in relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
Golidocitinib data extend from lymphoma into secondary HLH
An oral presentation will report updated results for golidocitinib monotherapy in adults with secondary hemophagocytic lymphohistiocytosis (HLH). The data extend findings shown at the European Hematology Association (EHA) Congress 2026. Dizal reports high and durable response rates with a manageable safety profile, which it says supports further development in the indication.
Additional golidocitinib presentations cover first-line use with CHOP, two real-world retrospective studies in r/r cutaneous T-cell lymphoma (CTCL) and mycosis fungoides, and a preliminary study combining the drug with PD-1 blockade and asparaginase-containing immunochemotherapy in newly diagnosed and high-risk advanced extranodal NK/T-cell lymphoma.
Golidocitinib is described as the world's first and only JAK1 inhibitor approved for r/r peripheral T-cell lymphoma (PTCL). China's National Medical Products Administration approved it in June 2024. At a data cut-off of August 31, 2023, the objective response rate was 44.3% and the complete response rate 23.9%. Median duration of response reached 20.7 months per independent review, and median overall survival was 24.3 months as of February 2024. The U.S. FDA granted Fast Track Designation for r/r PTCL in February 2022.
Birelentinib targets first-line CLL/SLL as monotherapy and with venetoclax
Two oral presentations will cover birelentinib, a non-covalent LYN/BTK dual inhibitor, in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). The drug is designed to inhibit both BTK-dependent and BTK-independent B-cell receptor signaling.
As monotherapy, birelentinib showed antitumor activity, durable responses and favorable tolerability in treatment-naïve and heavily pre-treated patients. A global, randomized Phase 3 study is ongoing against investigator's choice of treatment in r/r CLL/SLL. In combination with venetoclax in treatment-naïve patients, Dizal reports encouraging efficacy and good tolerability regardless of high-risk genetic features.
The FDA granted birelentinib Fast Track Designation in August 2025 for adults with r/r CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
GW5282 debuts in r/r NHL with a dual EZH1/2 mechanism
GW5282 inhibits EZH1 and EZH2 with equal potency, aiming to prevent tumor escape through compensatory EZH1 activation. Dizal says approved EZH2-only inhibitors have short plasma half-lives. That requires higher dosing, which brings a high pill burden, gastrointestinal adverse reactions and dose-limiting bone marrow toxicity.
According to Dizal, GW5282 shows high oral bioavailability, a longer half-life, a reasonable daily dose and improved bone marrow safety. Emerging data show an encouraging safety profile and clinical efficacy across multiple r/r NHL subtypes. GW5282 and the 4th-generation EGFR TKI DZD6008 are in post proof-of-concept studies.
CEO Xiaolin Zhang said the ASH presence reflects progress in T-cell and B-cell lymphomas as well as autoimmune diseases.